Switchpoint Bio's $5.3M Pre-Seed Targets Drug Response

Lead

Switchpoint Bio, a startup split between Helsinki, Finland and Cambridge, Massachusetts, has emerged from stealth with a $5.3M pre-seed round. Treehouse Delmar Investments supplied $5M of it, which makes the round close to a single-investor financing. The company is building a platform that reads DNA methylation patterns in circulating immune cells, with the aim of showing drug developers what changes in a patient's biology during treatment and why some patients do not improve.

What Does Switchpoint Bio Actually Do?

Switchpoint Bio profiles epigenomic marks, chemical tags on DNA that shift with disease, environmental exposure and therapy, using targeted methylation sequencing on blood samples. It pairs that data with AI models to identify disease-relevant immune states and follow them over time.

The pitch is practical. Tracking a drug's biological effect in tissue usually means repeated biopsies, which are invasive and rarely done at scale. A routine blood draw, repeated across a trial, would be cheaper and easier on patients, if the signal holds up.

The company is testing the approach in autoimmune disease, starting with systemic lupus erythematosus. Lupus is a condition where treatment response varies widely between patients, which makes it a reasonable proving ground.

Who Is Behind the Company and the Round?

CEO Samuel Myllykangas co-founded Switchpoint with Jason Buenrostro, the inventor of the ATAC-seq method, after the two developed targeted sequencing technologies together at Stanford. Myllykangas previously built Blueprint Genetics, the Finnish genetic diagnostics company that Quest Diagnostics acquired in 2020. Niilo Färkkilä, a former Amgen and GSK executive, is chief commercial officer, and Jussi Paananen, another Blueprint Genetics alumnus, is chief technology officer. Mitja Kurki, whose background includes FinnGen and the Broad Institute, is a scientific advisor.

Dave Proctor of Treehouse Delmar said the firm is "proud to support" a team that pairs scientific talent with "a real path to turning breakthrough biology into evidence that helps patients." The company founded in 2025 did not disclose a valuation, and no other named investors joined the round.

Why Does a Near-Single-Investor Pre-Seed Matter?

A $5.3M pre-seed is large for the stage, and the concentration says something about the round. One backer carrying 94% of the money suggests a conviction bet on the founding team, particularly given Myllykangas's earlier exit, rather than a syndicate formed around a validated product.

That cuts both ways. Concentrated backing means fast decisions and fewer investors to satisfy. It also means the company has not yet been tested by a competitive lead process or by outside investors pricing the science. With valuation and the minor investor undisclosed, the market has little to benchmark against.

What Will the Money Fund?

Switchpoint plans to spend the capital on four things: clinical and industry validation, larger clinical and biobank datasets, further development of its epigenomic and AI platform, and hiring across Helsinki and Cambridge. The company is also in talks with pharmaceutical companies, although it named no partners.

Pharma validation is the step that decides whether this becomes a business. Drug developers already run biomarker programs, and a new blood-based assay has to show it adds information that existing genetic, proteomic or transcriptomic readouts do not. Epigenomic profiling from blood is also not a new idea in research, so the company's claim rests on scale and repeatability, which Myllykangas framed as making "biological switchpoints visible from a routine blood sample, repeatedly and at the scale required for drug development."

What Comes Next for Switchpoint Bio?

The near-term milestones are data, not revenue. Longitudinal lupus results showing that blood methylation tracks treatment response would give the company something concrete to take to pharma partners. Without them, the platform remains a research tool with a thesis.

If the early data are convincing, a seed round led by outside investors is the logical next step, and that round would put a price on the company for the first time. If they are ambiguous, a pre-seed of this size gives the team room to extend the datasets before raising again.

Outlook

Switchpoint Bio enters the market with an experienced founding team, a single committed backer and a defined first indication. What it lacks, for now, is published validation and a disclosed valuation. The lupus results and any named pharma collaboration will show whether blood-based epigenomics can move from research method to a standard part of drug development.